ZLDPF (ZLDPF) Stock Price & Analysis
ZLDPF (ZLDPF) rose 8.46% to USD 42.03 as of June 10, 2026 at 01:05 UTC, according to Nexqual real-time market data.
ZLDPF last closed at USD 38.75; the session ranged USD 42.03–43.21 on volume of 300 shares. Market capitalization is $2.94B, with a 52-week range of USD 35.93–83.12 (PNK). Source: Nexqual, June 10, 2026 at 01:05 UTC.
Key Statistics (as of June 10, 2026 at 01:05 UTC)
| Price | USD 42.03 |
|---|---|
| Change | ▲ 8.46% (up) |
| Previous Close | USD 38.75 |
| Open | USD 43.21 |
| Day Range | USD 42.03 – 43.21 |
| 52-Week Range | USD 35.93 – 83.12 |
| Volume | 300 shares |
| Market Cap | $2.94B |
| Exchange | PNK |
Technical Analysis (ZLDPF)
Nexqual's technical model rates ZLDPF "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.89 (neutral) |
| vs SMA50 | Below (USD 47.92) |
| MACD | -1.08 (negative) |
Analyst Ratings (ZLDPF)
Wall Street analysts rate ZLDPF "None", per Nexqual as of June 10, 2026 at 01:05 UTC.
| Consensus Rating | None |
|---|
Earnings (ZLDPF)
| Next Earnings Date | 2026-05-07 |
|---|---|
| Revenue Estimate | $2.40B |
Source: Nexqual, June 10, 2026 at 01:05 UTC.
Financials & Fundamentals (ZLDPF)
| Total Revenue | $9.24B |
|---|---|
| Revenue Growth (YoY) | +325.00% |
| Gross Margin | +99.99% |
| Operating Margin | -1585.29% |
| Profit Margin | +69.21% |
| ROE | +56.16% |
| Debt / Equity | 2.86 |
| Current Ratio | 37.17 |
| Total Cash | $14.47B |
| Total Debt | $414.00M |
| Free Cash Flow | $4.22B |
Source: Nexqual, June 10, 2026 at 01:05 UTC.
Financial Health Score (ZLDPF)
Nexqual rates ZLDPF's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 01:05 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $14.5B cash vs $414M debt, net cash position |
| Cash Flow | Strong — FCF $4.22B, 46% margin |
| Efficiency | Strong — ROE 56%, ROA 34.7% |
Ownership (ZLDPF)
| Insider Ownership | +0.53% |
|---|---|
| Institutional Ownership | +51.03% |
| Shares Outstanding | 69.96M |
| Float | 56.67M |
Source: Nexqual, June 10, 2026 at 01:05 UTC.
Leadership (ZLDPF)
ZLDPF is led by Adam Sinding Steensberg (age 51), President & CEO, per Nexqual as of June 10, 2026 at 01:05 UTC.
| President & CEO | Adam Sinding Steensberg (age 51) |
|---|---|
| EVP & CFO | Henriette Wennicke (age 42) |
| Executive VP & COO | Ivan Mourits Moller |
| Executive VP & Chief Scientific Officer | Utpal Singh (age 51) |
Major Backers & Investors (ZLDPF)
Notable institutional backers of ZLDPF include SmallCap World Fund Inc, EuroPacific Growth Fund-EUPAC Fund, American Century ETF Trust-Avantis International Small Cap Value ETF, according to Nexqual as of June 10, 2026 at 01:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| SmallCap World Fund Inc | 3.42% |
| EuroPacific Growth Fund-EUPAC Fund | 2.57% |
| American Century ETF Trust-Avantis International Small Cap Value ETF | 0.86% |
| Fidelity | 0.78% |
| Goldman Sachs | 0.73% |
| College Retirement Equities Fd.-College Retirement Equities Fd. - Tota | 0.67% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4% |
| BlackRock | 0.65% |
Source: Nexqual, June 10, 2026 at 01:05 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BVNKF | Bavarian Nordic A/S | USD 29.41 | ▲ 5.72% |
| TLPPF | Telix Pharmaceutical Ltd. | USD 9.5 | ▲ 0% |
| IVBXF | Innovent Biologics Inc. | USD 10.76 | ▲ 6.6% |
| BFFAF | BASF SE | USD 61.5 | ▲ 7.12% |
| GNMSF | Genmab A/S | USD 249 | ▼ 0.18% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:05 UTC. This page is informational and not investment advice.